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Beyond "Bad News": The Diagnosis, Prognosis and
Classification of Lymphomas and Lymphoma
Patients in the Age of Biomedicine (1945-1995)
PETER KEATING and ALBERTO CAMBROSIO*
Prognosis and the Development of Clinical, Pathological and
Biological Classifications
Historians have long recognized that medical prognosis, along with diagnosis and treat-
ment, constitute thebackbone ofclinical medicine.1 Theyhaveobserved, forexample, that
even in the depths of late-nineteenth-century therapeutic nihilism, physicians did not
hesitate to prognosticate.2 Medical sociologists have recently identified an increasing
demand forprognostic information and aheightened interest in itspractice. NAChristakis
has singled out the growing prevalence of chronic disease, and new forms of medical
technology, including those associated with reproduction and the new genetics, as well
asefforts directed towards costcontainment as causes ofthisrenewedinterestanddemand.
Confronted with this demand, clinicians have sometimes hesitated before pronouncing on
thefuture.3Philosophers have suggestedthatpartoftheclinicians' reluctance topredictlies
inthefactthatmodemprognostic information comesfromstatistics aboutclasses or groups
ofpatientsand sodoesnotapplydirectly toindividuals.4Theproblemofprognosisisfurther
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3N A Christakis and G A Sachs, 'The role of
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'Incurable suffering from the "hiatus theoreticus"?
Some epistemological problems in modem medicine
and the clinical relevance ofphilosophy ofmedicine',
Theor.Med.Bioeth., 1998, 19: 229-51.Philosophersof
clinical medicine also tell us, somewhat implausibly,
that "[a] prognosis is a prediction of what the future
stageofdiseasewillbe,regarding asinglecaseanditis
not an inherentcharacteristic ofthepatientoran innate
part of the (so-called) natural history of the disease";
Dominick A Rizzi, 'Medical prognosis: some
fundamentals', Theor. Med., 1993, 14: 365-75, p. 368.
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compoundedbythefactthatevenwhenanindividualprognosisismade,itcannot,exceptby
definition, be easily detached from the biology of the individual or the natural history of
disease. Indeed, practitioners readily admit that "[t]he two fundamental processes in med-
icine, thoseofdiagnosis andprognosis, areconfusedattimes".5 Ascanbeeasilyimagined,
any diagnosis produces some kind ofprognosis if only that of "future uncertain".
The intertwining ofdiagnosis and prognosis can be explored in many ways. No matter
how this is done, however, it must be admitted that the post-war rise of that novel epis-
temological, social andinstitutional fusionofbiology andpathologyknownasbiomedicine
provides the context within which these evolving relations must firstbe examined.6 In this
paper we explore the evolution ofrelationships between clinical or prognostic classifica-
tions and those (mainly diagnostic) developed in adjacent areas of biomedicine such as
pathology andhistology. Wefocusinparticularonthecontinuing attemptssincetheSecond
World War to relate clinical research findings to biological and pathological findings
and to develop standards that allow clinical researchers to compare across clinical trials.
Despite constant pressure from both biology and pathology to align classifications with
theseexternal, andtherefore, more "objective" standards,clinicalresearchhasattemptedto
maintain its own criteria ofrelevance and success in the constant revision ofits norms and
forms. Nonethe less, clinical classifications havebecomeincreasingly based onbiological
andpathological findings. Indeed, partly due to the increasing role playedby multi-centre,
co-operative clinical trials inmodern cancertherapy, independent "prognostic" classifica-
tions have emerged to organize, collate and standardize forms of information formerly
contained within diagnostic categories.
Suchtensionsmayseemobviousfromapragmaticpointofview.Inadditiontoconnecting
individual patients to larger biological and pathological categories, clinical classifications
that "stage" tumours according totheiranatomic extentorspread, orthat "grade" tumours
according to their aggressivity depending upon their histological appearance at biopsy,
determine therapeutic choices. In this sense, the purpose ofclinical classifications clearly
goesbeyondthemerearticulationofthe "art" oftherapywiththemorefundamental "scien-
tific" categories ofpathology andbiology. It is equally obvious, however, that anefficient
andusefulstagingsystemisnotnecessarilyveryenlighteningwithregardstothepathological
mechanisms underlying the emergence and spreadofthedisease inquestion. Similarly, the
classification ofdiseases according to their histopathology may not be the most adequate
reflectionofthemolecular-biological entitiesatplayintheprocess. Finally,orderingpatho-
logicalentities according totheirbiological substratum orconstituents maycontributelittle
to theirimmediate clinical management. In short, there are anumberofproblems attendant
upon the articulation and confrontation ofthe various kinds ofclassifications.
As an illustration ofthese remarks, we have chosen to examine the evolution ofclinical
andhistopathological classifications ofthelymphomas. Thiscategoryincludestwodistinct
yetrelatedclasses ofdisease: Hodgkin's diseaseandthenon-Hodgkin's lymphomas. These
two classes allow us to develop acomparison and show that, forexample, whereas clinical
staging emerged ahead of and in some respects outside of biological and pathological
5Mary Gospodarowicz etal., 'Prognostic factors in 6For a description of biomedicine and its specific
clinical decisionmaking: thefuture',Cancer, 2001,91: epistemic and institutional contours, see Peter Keating
1688-95, p. 1688. and Alberto Cambrosio, 'Biomedical platforms',
Configurations, 2000, 8: 337-87.
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theories ofthe spread ofthe disease inthe caseofHodgkin's disease, attempts todevelop a
similarstagingsystemforthelymphomaswerenotsosuccessful. Giventhatworkcontinues
within this enterprise, ourremarks shouldbe considered more exploratory than definitive.
Wecannonethelessstateattheoutsetthatitisnotsomuchthatdiagnosisandprognosisare
confused, asthat: (1) manyclassifications ofthe sameentity orperson arepossible depend-
ing upon the purpose ofthe classification, and (2) a single classification may contain both
diagnostic andprognostic dimensions. In otherwords, it seems thatclassifications respond
to multiple agendas.7
Consider, for example, the following case of an individual diagnosed with non-
Hodgkin's lymphoma (NHL):
I was diagnosed April 1, 1996. I had a swollen neck gland and the back of my tongue had a huge
hump on it. The ear, nose and throat doctor took apiece offthe back ofmy tongue, sent me overfor
X-rays and a CT scan (both negative by the way). I went back to the ENT doctor in two days and he
gave me the bad news: large B-cell NHL, diffuse. I then went to an oncologist friend who I had
known-for twenty-five years, though not professionally. He did bone marrow studies, a spinal fluid
analysis, more CT scans, all kinds of blood work and put me to sleep for a gastroenterology look-
see ... all negative, so he staged it HA, high grade.... After seven CHOP [chemotherapeutic]
treatments, I had radiation to the neck area every day for fourweeks. I was left with very painful yet
numb feet, and tingling in my left arm, which is still there.8
Thisinitialdiagnosiscontained,inspiteofitsneutralpresentationasascientificobservation,
aform ofprognosis, which thepatienttermed "badnews". As we will see, specification of
the lymphoma as "large B-cell NHL, diffuse" already says a lot about what is expected to
happen to thepatient andwhatisexpected tohappen to the disease. Secondly, when such a
category ofdiseaseis "staged" asin "HA,highgrade", morethanprognosis-fortheseare
indeed prognostic terms-is at stake. In order to reach such a conclusion, clinicians and
laboratory investigators necessarily undertook anexplorationofthebiology oftheentity in
question-described, for example, its targets and its spread-thus further specifying the
diagnosis. As in the world ofLaplacian physics, a complete diagnosis would result in an
exact prognosisjust as an exact prognosis would presuppose a complete diagnosis.
In whatfollows, ourdiscussion will include both Hodgkin's disease andnon-Hodgkin's
lymphomas in recognition of the fact that there has been a continual evolution in the
relation between the lymphomas and the disease first described by Thomas Hodgkin in
1832. Although the name "non-Hodgkin's lymphomas" seems to suggest that Hodgkin's
disease is a lymphoma, the two have been treated both clinically and pathologically quite
separately since the endofthe SecondWorld War. Theirdivergentevolution allows us the
opportunity to make a number ofcomparative remarks concerning the complex relations
thatexistbetweenprognostic anddiagnosticclassifications, andthemanifoldwaysinwhich
biomedical innovation may transform these relations.
Since the beginning ofthe twentieth century, Hodgkin's disease has been defined as a
discrete histopathological entity on the basis ofthe presence of a giant cell known as the
Reed-Steinberg cell. The histopathological distinctiveness ofHodgkin's disease escaped
7See Geoffrey C Bowker and Susan Leigh Star, 8Lorraine Johnston, Non-Hodgkin's
Sorting things out:classificationanditsconsequences, lymphomas: making sense ofdiagnosis, treatment
Cambridge, MA, MIT Press, 1999, esp. 'Part One: and options, Sebastopol, CA, O'Reilly, 1999,
Classification and large scale infrastructures'. p. 132.
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Hodgkinhimself, whoworkedwithoutamicroscope. Indeed, subsequentreviewsofHodg-
kin's original sevenbiopsy specimens have shownthatonly two wouldtodaybediagnosed
histologically as Hodgkin'sdisease, theothers fallingunderthecategory ofnon-Hodgkin's
lymphomas (NHLs) or, the great confounder of the nineteenth century, tuberculosis.9 In
recent times, however, this histopathological distinction has faded. The redefinition ofthe
Reed-Stemnberg cellsas(inmostcases)B cellshaseffectivelybrokendownthehistological
barrierbetween Hodgkin's disease andthenon-Hodgkin's lymphomas andhasbroughtthe
two together in the latest histopathological classification of the lymphomas (the REAL
[Revised European-American Lymphoma] classification). Nonetheless, partly inrecogni-
tionofitsclinicalspecificity, andpartlybecauseofprofessional andinstitutional inertia,the
term Hodgkin's disease is still widely used even though, as some pathologists argue,
Hodgkin's disease should be called Hodgkin's lymphoma.10
The present histopathological unity is, however, ofrecent origin. There have been long-
standing andpersistent differences intheclinicalclassifications usedtomanageHodgkin's
andNHLpatients. Beforeturning tothesedifferences, letusfirstnotethattherehasbeen an
evolution in the kinds ofclinical classifications used in the field ofcancer in general that
correspondstotheriseofpost-warclinicalresearch.Thefirstandoldestclassifications were
based on the clinical descriptions of disease that had accumulated since the eighteenth
century and that correlated anatomic and clinical findings in the form of clinical
"'pictures".1 The "pictures" offered notonly a symptomology ofthe disease and a semio-
ticsforitsdiagnosis, but, indescribingthenatural history orcourseofthedisease, provided
aprognosis that wasgenerallyratherbleak. Sincetheendofthe SecondWorldWarandthe
advent oflarge-scale chemotherapy, various schemes that determine predictive stages in a
disease's progress and prognostic indices (composed of a variety ofbiological and patho-
logical indicators) have replaced the original clinical pictures as sources of prognostic
information. Moreover, giventhatcancernowrarely goesuntreated, clinicians oftenprefer
9See R N Poston, 'A new look at the original cases
of Hodgkin's disease', Cancer Treat. Rev., 1999, 25:
151-5. For previous reviews, see H Fox, 'Remarks on
the presentation of microscopical preparations made
from some of the original tissue described by Thomas
Hodgkin, 1832', Ann. Med. Hist., 1926, 8: 370-4;
W St C Symmers, 'The lymphoreticular system', in
W St C Symmers (ed.), Systemic pathology, vol. 2,
Edinburgh, Churchill & Livingstone, 1978, pp.
504-892; K Lennert, 'Die Beziehungen von Hodgkin-
und non-Hodgkin-Lymphomen', Arzneim-Forsch./
Drug Res., 1987, 37: 255-9.
10Acommittee ofexperts, manyofwhomhadbeen
involved in the formulation of the 1994 REAL
classification, working for the WHO recently failed to
reach a conclusion on this score. Pathologists on the
committee felt that the term Hodgkin's disease should
be abandoned in favour of Hodgkin's lymphoma.
Other members of the committee felt the change
"unnecessary". See N L Harris et al., 'The World
Health Organization classification of neoplastic
diseases of the hematopoietic and lymphoid tissues.
Report of the Clinical Advisory Committee, Airlie
House, Virginia, November, 1997', Ann. Oncol, 1999,
10: 1419-32, p. 1430. For the evolving relations
between Hodgkin's and non-Hodgkin's lymphomas,
see N L Harris, 'The many faces ofHodgkin's disease
around the world: what have we learned from its
pathology?', Ann. Oncol., Supplement, 1998, 9:
S45-S56; Karl Lennert, 'Borderlands of pathological
entities', in Ian T Magrath (ed.), The non-Hodgkin's
lymphomas, 2nd ed., New York, Oxford University
Press, 1997, pp. 133-67, esp. 133-7; Elaine S Jaffeand
Konrad Mueller-Hermelink, 'Relationship between
Hodgkin's disease and non-Hodgkin's lymphomas',
in P M Mauch et al. (eds), Hodgkin's disease,
Philadelphia, Lippincott, Williams and Wilkins
1999, pp. 181-93.
1 Beginning with Sydenham (among others), see
Knud Faber,Nosography in modern internal medicine,
New York, Paul B Hoeber, 1923, and Owsei Temkin,
'The scientific approach to disease: specific entity
and individual sickness', in A C Crombie (ed.),
Scientific change, London, Heinemann Educational,
1963, pp. 629-47. In the seventeenth century and the
revival of clinical description, the anatomo-clinical
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the term "treated history" over "natural history".'2 Prognosis, in other words, has been
separated from diagnosis even though, as previously noted, knowledge of one generally
entails knowledge of the other.
The mostwidespread ofthe aforementioned staging schemes in the field ofcanceris the
TNM (tumour, node, metastasis) system. Although, for anatomical reasons, the TNM
system cannot be used to stage lymphomas, its extra-clinical origin does bear mention.
Not originally intended to direct treatment management, the TNM system grew out of
French wartime efforts to develop a nomenclature for a public health enterprise known as
the Permanent CancerSurvey. Organizedby theNational Hygiene Institute, the Survey set
out in 1943 to create a cancer register, including all cases ofthe disease treated in cancer
centres. Initial results showed, however, that uniform categorization of the cancers was
consistently compromised by the fact that the same "histological" cancer could be regis-
tered under a variety of names depending upon the anatomical extent of the disease. To
overcometheproliferationofentitiesbasedonanatomicalextent,PierreDenoix,directorof
the project, proposed standardization in reporting of the latter.'3 Denoix developed this
standardized system throughout the 1950s, at the end of which it was adopted by the
International Union Against Cancerfortumours ofthe breast and larynx, andthen became
an international standard.'4
While the clinical classification ofthe lymphomas participated in this overall evolution
frompicturetostages, itdidsoinitsownway. BythetimetheTNM systemhadbeenwidely
adopted in the 1960s, clinical researchers had already developed staging schemes and
clinical classifications for the lymphomas. It is to these that we now turn.
The Diagnosis and Prognosis of Hodgkin's Disease
Pathological and clinical classifications, although overlapping, were indeed distinct. In
order to understand the contrastbetween the two kinds ofclassification, we begin with the
classifications developedbypathologists forHodgkin'sdisease. Intheimmediatepost-war
period, threetypes ofHodgkin'sbasedonthecellularappearances instainedtissue samples
were recognized.'5 These were not hard and fast distinctions: in an extended series of
biopsies conducted at the US Army Institute ofPathology, R Philip Custer and William G
Bernhard noted that less than 25 per cent of cases fell into a single histopathological
category, indicating considerable fluidity between the three types.16 Custer and Bernhard
concluded thatnotonly weredivisions withinthediagnosis ofHodgkin's artificial, butthat
method is often said to have been perfected in early- Paris, International Union Against Cancer, 1958.
nineteenth-century Paris. See Caroline Hannaway and See in general, Leslie H Sobin, 'TNM:
Ann La Berge (eds) Constructing Paris medicine, principles, history, and relation to other
Amsterdam and Atlanta, Rodopi Editions, 1998. prognostic factors', Cancer, Supplement, 2001, 91:
12See for example, Gospodarowicz et al., op. cit., 1589-92.
note 5 above, p. 1691. 15These are the divisions presented by
13See Marie Menoret, 'The genesis of the notion H Jackson and F Parker, Hodgkin's disease and
of stages in oncology: the French permanent cancer allied disorders, New York, Oxford University
survey (1943-1952)', Soc. Hist. Med., 2002, 15: Press, 1947.
291-302. 16R Philip Custer and William G Bernhard, 'The
14UICC Committee on Clinical Stage interrelationship of Hodgkin's disease and other
Classification and Applied Statistics, Clinical lymphatic tumors', Am. J. Med. Sci., 1948, 216:
stage classification andpresentation ofresults, 625-42, p. 633.
malignant tumors ofthe breast and larynx,
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the lymphomas as a whole blended into each other to such a degree that "a rigid sub-
classification of lymphatic tumours is artificial and confusing"'.'7
Inthefirstdecadeofthetwentiethcentury,clinicianshadalsosub-categorizedHodgkin's
intoaseriesofclinicalpictures.18BytheeveoftheSecondWorldWar,furtherclinicalwork
had subdivided these "pictures" according to several courses ofevolution. Following the
French specialists, Paul Chevalier andJeanBernard, the Swissradiotherapist Rene Gilbert
haddelineatedfourvarietiesofevolution.19Theirdiagnosisdemandedconsiderableclinical
acumen for they were combined with a further eleven different lymphatic and extralym-
phatic forms. Experts inradiotherapy such as Gilbert20 believedthatthese clinical variants
precluded any possible standardization of treatment. When combined together with the
problem ofshifting histopathology, Gilbert, unsurprisingly, had this to say about standar-
dization just before the outbreak of the Second World War:
By its polymorphism and by the great variation in its evolutionary features in different cases ... the
disease presents great diagnostic and therapeutic difficulties. Its treatmentcannot be standardized; it
must always be adapted to each particular case and, on the part ofthe treating physician, requires
much clinical sense.21
None the less, standardization is precisely what happened in the post-war period.
Lloyd F Craver, physician at the Sloan-Kettering Memorial Hospital in New York and
one of the administrators ofthe first cancer chemotherapy trials conducted with nitrogen
mustardjustafterthewar, tookthefirst stepinthe standardizationprocess. Forclinicaltrial
purposes, he organized the multiple clinical pictures into three classes of disease:
(I) localized; (II) regional (above orbelow the diaphragm); and (III) generalized, the latter
having been singled out for nitrogen mustard therapy.22 To go from classes to stages,
however, required a further step. In a series of papers published in the 1950s and now
regarded as "classics",23 Vera Peters at the Toronto General Hospital subtly transformed
17Ibid., p. 641.
'8See for example, KurtZiegler, DieHodgkinsche
Krankheit, Jena, G Fischer, 1911. Karnofsky has
analysed the relationship between these pictures and
present-day stages in DavidAKarnofsky, 'Thestaging
ofHodgkin's disease', CancerRes., 1966, 26: 1090-4,
pp. 1090-1.
'9See Rene Gilbert, 'Radiotherapy in Hodgkin's
disease (Malignant Granulomatosis): Anatomic
and clinical foundations; governing principles;
results',Am.J.Roentgenol. & Rad. Therapy, 1939,41:
198-241, p. 204. The Chevalier and Bernard
classification of the forms of evolution can be
found in P Chevalier and J Bernard, La maladie de
Hodgkin (lymphogranulomatose maligne), Paris,
Masson, 1932.
20Gilbert is generally credited with having put
radiotherapy of Hodgkin's disease on the map in the
inter-war period. Henry Kaplan, for example, credited
Gilbert with having invented enlarged field radiation
techniques; viz. irradiation of the entire lymph node
chain rather than the specific area of involvement.
As Gilbert did use control, post-war radiotherapists
imbued with the notion of a clinical trial had "a
tendency to dismiss his apparently superior results as
being due to case selection". Henry S Kaplan, 'The
radical radiotherapy ofregionally localized Hodgkin's
disease', Radiology, 1962, 78: 553-61, p. 553. See
also,MauriceTubiana, 'Developmentoftheconceptof
Hodgkin's disease as a curable illness: the European
experience', in Mauch et al. (eds), op. cit., note 10
above, pp. 23-4.
21Gilbert, op. cit., note 19 above, p. 198.
22Lloyd F Craver, 'Recent advances in treatment
oflymphomas, leukemias and allied disorders: the
Buldey lecture', Bull. N. Y. Acad. Med., 1948, 24:
3-25, p. 12. See also, D P Slaughter and L F Craver,
'Hodgkin's disease; five year survival rate; value of
early treatment; notes on four cases oflong duration',
Am. J. Roentgenol. Rad. Therapy, 1942,47: 596-606.
This,inturn, wasanexpansionofDorothyReed's 1902
stages (Stage I: lymph node enlargement, Stage II,




23Saul A Rosenberg, 'Development ofthe concept
ofHodgkin'sdisease as acurableillness: theAmerican
experience', in Mauch et al. (eds), op. cit., note 10
above, pp. 47-57, on p. 47.
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Craver'sclasses24byevaluatingherpopulationofpatientstreatedattheTorontoGeneralin
terms of the factors that correlated with five- and ten-year survival rates. The most sig-
nificant prognostic factors turned out to be extent of anatomical involvement upon pre-
sentation ofdisease or, in otherwords, Craver's classes. Unlike the latter, however, Peters'
articulation ofthe classes with survival data enabled her to specify three stages based not
onlyonpresentationoftheanatomicextentofdisease,butalsoonresponsetotreatment. For
example, Peters defined stage one as more than "involvement of only one lymph node
region ora single lesion elsewhere, withnoconstitutional symptoms"; indeed, shewenton
to show that the five-year survival rate following radiotherapy was approximately 88 per
cent. Unlike the classes, then, the stages were correlated with treatment history and could
thus be construed as "truly" prognostic.
Thestagesthusoverlappedwithbutwerenotidenticaltotheclinicalpicturesorclasses.In
particular, Peterswentoninthesamepapertousethestagesinacomparisonoftwoformsof
irradiation therapy; one with andonewithoutprophylactic radiation. Inotherwords, Peters
made uniform therapy possible-impossible, we recall, according to Gilbert-by dividing
the disease into stages andputting patients into the stages ratherthan drawing increasingly
complicated "forms" inanattempttogatherpatientsintoacomplex seriesof"pictures".25
More than a description, stages set out prescriptions or rules for therapeutic intervention.
An additional consequence ofPeter's scheme was that, by reporting treatment results in
terms of clinical classification, she described the evolution of the disease under specific
therapeutic regimes; a "treatment history" as opposed to a "natural history". Peters'
approach not only constituted a decisive step in the standardization of treatment but
also overcame the initial obstacle to that standardization, the cloudy picture presented
by the somewhat fluidpathology. Peters' scheme also showedthe "clinical" classification
to be superior to the "pathological" classification in terms ofprognosis. In particular, she
concluded as a result of her findings that "the pathological picture is a very necessary,
indeedtheonlyproofofthediagnosis, butinestablishing theprognosis itacts as avaluable
aid,butisnotasconclusiveastheclinicalfactors".26RobertLukes,whoin 1954hadbecome
head of the Lymphatic Tumor Division at the US Armed Forces Institute of Pathology,
recognized this novelty in Peters' method when, reviewing previous histopathological
classifications in the early 1960s, he wrote:
The application of a clinical staging method by Peters to survival studies in Hodgkin's disease and
in the evaluation ofthe effectiveness ofradiation therapy without regard to histologic classification
presented a new analytic approach.27
24See M Vera Peters, 'A study of survivals in results according to athree-stage clinical classification
Hodgkin's disease treated radiologically', Am. J. that also included the presence or absence ofsystemic
Roentgenol., 1950, 63: 299-311; M Vera Peters and symptoms. By doing this, she started a new era of
K C H Middlemiss, 'A study of Hodgkin's disease rational emphasis on diagnostic evaluation and
treated by irradiation', Am. J. Roentgenol., 1958, treatment reporting based on the anatomic extent of
79: 114-21. involvement." Gianni Bonadonna, 'Historical review
25As Gianni Bonadonna has noted in a recent of Hodgkin's disease, Br. J. Haematol., 2000, 110:
appreciation ofPeters' work, thelatterwentbeyondthe 504-11, on p. 10 out of 16 from download.
clinical simplification and improved treatment: 26Peters, op. cit., note 24 above, p. 307.
"Important from many points of view were the initial 27Robert J Lukes, 'Relationship ofhistologic
publications by Peters, who, with Gordon Richards, features toclinical stages inHodgkin'sdisease',Am.J.
between 1928 to 1953, used a treatment plan very Roentgenol., 1963, 90: 944-55, p. 944.
similar to that ofGilbert. First, she reported treatment
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Indeed, inverting the pathology-clinic hierarchy, Lukes went on to use Peters' stages to
evaluate clinically the histopathological classification "established on the basis of the
author's [Lukes'] experience with over 3,000 cases of Hodgkin's disease while Chief of
the Hematopathology Section of the Armed Forces Institute of Pathology from 1954-
1962 .28 Lukes' comparison showed his histological types to be distinctly superior to
previous pathological classifications in so far as, when correlated with the clinical stages,
they dissipated much of the fluidity that had been associated with the histopathological
subtypes.29
In addition to the advances in radiotherapy, the role ofchemotherapy was considerably
enhanced during Lukes' tenure at the US Armed Forces Institute of Pathology. Initial
experiments with nitrogen mustard carried out in the late 1940s by researchers like Craver
at Sloan-Kettering were greatly expanded in 1955 with the formation ofthe co-operative
clinical trials groups organized by the National Cancer Institute (NCI) to conduct large-
scale, multi-institutional stage two and stage three clinical trials. The programme grew
exponentially forthe first ten years, recruiting 1,000 clinicians and 16,000 patients in over
250 institutions in the largest clinical cancer trials ever seen.30 Promising results with the
leukaemias and the lymphomas had led C Gordon Zubrod, the head of the programme
at the NCI, to create a series of task forces in 1963 specifically targeting the leukaemias
and the lymphomas.
The developmentofclinical trialsabroad, andtheemergingvariability intheapplication
of staging criteria in Hodgkin's disease, suggested the need for a standard international
classification system. Thus Peters' staging system and Lukes' new histopathological sub-
typeswereshowcasedattwointernational symposiaonHodgkin'sdiseaseheldin 1965, one
inParis31 andone inRye, New York. Atthe Paris meeting, Lukes' system shonethrough in
a negative manner when an international panel of three pathologists, including Lukes,
reported the results of a blind examination of 395 biopsies from six different hospitals.
The experts concluded that, although thecriteria forthe diagnosis ofHodgkin's were more
or less internationally equivalent, competing sub-classifications added little in terms of
prognostic information and that, in this respect, Lukes' system would be preferable as an
international standard.32
The proposals presented in Paris in February were resubmitted to the Rye symposium in
September 1965. Here, an international committee proposed the adoption of a slightly
modified version of Peters' system subsequently known as the Rye classification.33
28Ibid., p. 947.
29Ibid., p. 955. Lukes compared his own
classification explicitly with that developed by
Jackson and Parker, op. cit., note 15 above.
30These numbers concern the 22 co-operative
groups active in 1968 who were then conducting over
230 different studies. See 'Recommendations of the
cancer clinical investigation review committee and the
national advisory cancer council regarding the
cooperative clinical cancer research program',
National Cancer Institute, March 1968, p. 1.
31 For the conference report, see Maurice Tubiana,
'La radiotherapie de la maladie de Hodgkin:
Symposium international organise a Paris le 15 fevrier
1965', Nouv. Rev. Fr. Hematol., 1966, 6: 6-120.
32Robert J Lukes, C Gompel, and C Nezelof, 'Le
diagnostique histopathologique de la maladie de
Hodgkin. Analyse preliminaire d'une etude conduite a
l'aveugle sur 395 observations par trois pathologistes
de nationalite differente', Nouv. Rev. Fr. Hematol.,
1966,6: 11-15,p. 14. Lukespresentedhissystemusing
377 cases from the Armed Forces Institute of
PathologyCollection. SeeRJLukes,JButler,andEthel
B Hicks, 'Le pronostic de la maladie de Hodgkin
d'apres la variete histologique et le stade clinique',
Nouv. Rev. Fr. Hematol., 1966, 6: 15-22.
33The modification consisted of the addition of a
stagefourproposedbyKaplanin 1963.Thestages were
further sub-coded "A" (asymptomatic) or "B"
(symptomatic: fever, night sweats and itching). The
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Although itcontinuedthethemes attheParisconference, theRye symposiumalsooccurred
within a framework ofconferences that had been set up by the American Cancer Society
(ACS) in 1963, with additional financial support by the National Cancer Institute. The
planning committee consisted of members of the two task forces-the Acute Leukemia
TaskForceandtheLymphomaTaskForce-thathadrecentlybeenorganizedbytheNCI.34
InadditiontotheendorsementofPeters' stagingsystembythe "ClassificationCommittee",
the Nomenclature Committee also adopted Lukes' histopathological classification of
Hodgkin's disease. The latter had been further bolstered by interim studies mobilizing
theconsiderableclinical material atLukes' disposal,namelydatacollectedduringafifteen-
to eighteen-year follow-up study of 377 US Army cases from the Second World War.35
Morethanasimplecorrelation, Lukes' studiesshowedthatthepathologicclassification and
theclinicalclassificationcouldnot, infact, be sharplydistinguished. Both wererelatedto a
thirdvariable, thehostresponsetodisease.Ratherthananindependentvariable,theclinical
stage was, according toLukes, areflection ofacombination ofhostresponseandhistologic
type.36Thetwoclassifications-clinicalandpathological-thusbecameintertwinedandthe
detection ofthehistological class alone later became known as "pathological staging".37
There were, however, some hesitations that bear mention, as they illustrate some ofthe
initial confusion surrounding this alliance ofprognosis andpathology. Inparticular, given
that Lukes had constructed his histopathological types partly on the basis of prognostic
criteria, someRyeconferenceparticipants suspected thatLukeshadnotuncovereddistinct
types of Hodgkin's disease but simply different phases of the same bio-pathological
process. In the course of conference discussions, some researchers suggested that the
committee consisted ofMaurice Tubiana (Villejuif,
France); Eric Easson (Manchester, UK), Lillian Fuller
(Houston, USA), David Karnofsky (New York, USA),
Robert Lukes (Los Angeles, USA), Saul Rosenberg
(Palo Alto, USA) and Vera Peters (Toronto, Canada).
See SaulARosenberg, 'Reportofthecommitteeonthe
staging of Hodgkin's disease', Cancer Res., 1966,
26, p. 1310. Kaplan's stage four consisted of any
manifestation ofdisease beyond the spleen and lymph
nodes and thus included, for example, involvement of
the bone marrow, liver, skin, lung pleura, etc. See
Henry Kaplan, 'Hodgkin's disease', J. Am. med. Ass.,
1964, 190, p. 911. S A Rosenberg and H S Kaplan,
'Clinical classification of Hodgkin's disease: its
importance and the influence of general signs', Nouv.
Rev. Fr. Hernatol., 1966, 6: 51-4.
34That is Joseph H Burchenal, James T Grace,
Henry S Kaplan, Howard E Skipper, Arthur Serpick,
and C Gordon Zubrod. Symposium held at the
Westchester Country Club, Rye, New York, 13-15
September 1965. See Jack W Milder, 'Foreward',
'Obstacles to the control ofHodgkin's disease',
Cancer Res., 1966, 26: 1046.
35Fordetails, seeLukes,op.cit.,note27above;and
R J Lukes, 'Histologic features and clinical stages',
J. Am. med. Ass., 1964, 190: 914-15.
36In particular, "The histologic changes do appear
to be related to the anatomic extent of the disease. It
seems totheauthors, however, thattheanatomic extent
and rate ofprogression are related to the state ofthe
host, which is reflected by the histologic type. It
therefore appears that the anatomic extent or clinical
stage is the result of the state ofthe host and the
histologic typeratherthanthereverse". RobertJLukes
and James J Budler, 'The pathology and nomenclature
of Hodgkin's disease', Cancer Res., 1966, 26:
1063-83, p. 1073.
37Pathologic staging followed the introduction of
staging laparotomy (see above). The latter had shown
thedifficultyofaligningtheRyeclinicalstageswiththe
Rye histopathological categories in the sense that
institutions that did not undertake laparotomy were
likely to assign patients to different pathological
categories than those thatdid. Since thewholepoint of
the staging system was to allow for inter-institutional
comparisons, theriseandspreadofstaginglaparotomy
created a serious problem for the enterprise. The
solution adopted at the 1971 Ann Arbor conference
consisted of separating clinical staging from
histopathologyandcreating aparallel systemofstaging
referred to as "Pathologic Staging". John E Ultmann
and Edgar M Moran, 'Diagnostic evaluation and
clinical staging in Hodgkin's disease: usefulness and
problems of the Ann Arbor staging classification in
primary staging and staging in relapse', National
CancerInstitute Monograph, 1973, 36: 333-45,
on p. 333.
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variable speedwithwhichthediseaseprogressedexpressedbiological differencesbetween
patients, not differences between disease entities.38 This was, in fact, exactly how Lukes
andButlerhaddescribedthehistologic "types" ofHodgkin's disease whenthey notedthat
"[t]he histologic findings are regarded as reflections of differences in the state of host
responsiveness".39Inotherwords,Lukes' histologiccategoriescouldbetermedprognostic
in the sense that they represented different degrees of progression and variations in the
expression ofthe samedisease. They were therefore notdiagnostic inthe traditional sense:
theydidnotisolatedistinctdiseaseentities. Thisnewbiomedicalconfigurationofprognosis
and diagnosis had also produced a subtle shift in disease definition.
From Treated History to Natural History and Back Again
The shift from clinical pictures and classes to stages corresponded with a shift in the
conceptionofthenaturalhistoryofHodgkin'sandinthosewhowrotethathistory.Formerly
the purview ofpathologists like Lukes, the natural history ofHodgkin's became caughtup
in its treated history in the post-war era, as radiotherapists gained an unparalleled view of
the pathological process. More precisely, given that patients generally presented with
disseminated disease, pathologists had surmised that, like the leukaemias, Hodgkin's
arose as a multifocal disease. Widespread radiation therapy, however, transformed that
view when therapy and staging offered significant new evidence that Hodgkin's emerged
fromasinglepoint.40Astheforemostradiotherapists intheUnitedStates,theStanfordteam
of Saul Rosenberg and Henry Kaplan, noted in a landmark study of therapeutic failures
presented at the Rye conference, in cases where the disease returned following therapy the
site of the return was far from random:
85% of the patients in this study in whom high dose irradiation was followed by any subsequent
manifestation of disease, demonstrated disease, unrecognized in the initial evaluation, in areas
immediately adjacent to the treated fields.4'
Thetherapeutic consequencesofthemodelaccordingtowhichthediseasespreadorderly
through the lymphnodes,42 were clear: "in the initial approach to patients withHodgkin's
disease it is reasonable to treat not only the known areas of involvement, but the areas
immediately adjacent to the known disease".43 Known as "extended field" therapy, the
technique soon became standard in the United States and Europe "despite the difficulties
38"We are all aware that the disease proceeds at
a different tempo in different patients depending,
I think, upon genetic factors and the biologic
environment in which theseoperate". AntonioRottino,
'Discussion on: the clinical picture of Hodgkin's
disease', Cancer Res., 1966, 26: 1061-2, p. 1061.
39LukesandButler, op. cit., note36above,p. 1063.
More precisely, the numerous histologic expressions
found in Hodgkin's disease appear to represent
manifestations of differences in the host's response
rather than a mixed lymphoma as suggested by Lumb
and Berman. GLumb, Tumoursofthe lymphoidtissue,
Edinburgh, E & S Livingston, 1954; L Berman,
'Malignant lymphomas-Their classification and their
relation to leukemia', Blood, 1953, 8: 195-210.
40'Forthisproblem, seeJacksonandParker, op.cit.,
note 15 above; Gilbert, op. cit., note 19 above; and
Peters, op. cit., note 24 above.
41 S A Rosenberg and H S Kaplan, 'Evidence
for an orderly progression in the spread of
Hodgkin's disease', CancerRes., 1966, 26: 1225-31,
p. 1229.
42Thisdid notexplain how, forexample, onecould




43Rosenberg and Kaplan, op. cit., note 41 above,
p. 1229.
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associatedwithexecution".44Inthecourseofthe 1950sand 1960s,therefore,anessentially
clinical-prognostic system-staging-transformed understanding ofthe pathophysiology
ofHodgkin'sbyordering treatmentresults in areasonably consistent andcoherentfashion.
In turn, the renewed understanding of the pathological process transformed therapeutic
rationale and modalities.
Even though subsequent clinical statistics generally confirmed Kaplan andRosenberg's
theory of progression, a variety of stances vis-a-vis the theory itself were possible.
Peters, for example, although she adhered to the therapeutic prescriptions of Kaplan
and Rosenberg, did not endorse a simple monofocal theory of the origin of the disease.
Instead, Peters contended that there were two types: unifocal andmultifocal.45 Basing her
position on the clinical observation that most ofthe patients presenting with early disease
wereyoungandpresentedwith alocalorregional swelling, shefurtherobservedthatshort-
termsurvivorsconsistedmainlyofelderlypatientspresentingwithconstitutionalsymptoms
which suggested a multifocal origin.46 Unlike Peters, Joseph Sokal of the Roswell Park
Cancer Institute in Buffalo accepted neither the pathology nor the therapeutic
consequences. At a general session on radiotherapy following the Rosenberg and Kaplan
presentation at the Rye conference, Sokal accused the two ofexaggeration:
Dr. Rosenberg implied that orderly progression is observed in 80% of patients with Hodgkin's;
others might say 20%. Orderly progression of itself does not prove the case for irradiation of
apparently uninvolved areas. The hazard of not irradiating an area which may be minimally
involved has been exaggerated by Dr. Kaplan. These areas can usually receive tumoricidal doses
just as effectively at a later date.47
Both Rosenberg and Kaplan admitted during the session that their study did notprove that
Hodgkin's had a unifocal centre but rather that it lent the notion "a high probability".
Not only did this novel conjoining ofprognosis and diagnosis generate new hypotheses
concerning the pathology of Hodgkin's, but it allowed the study of the pathology to be
pursued within the framework of clinical research. In fact, Kaplan and Rosenberg had
alreadyinitiatedaclinicaltrialtoexaminetheprocess,thepreliminaryresultsofwhichthey
presented atRye.48 As thetrialhadbeenunderway foronly three years, comparisons could
notbe made. However, twodiagnostic innovations ofthe 1960s hadexpandedexploration
of the biology of the disease beyond the original biopsy and the physical examination to
include both alymphangiogram (which allowed visualization oftheretroperitoneal lymph
nodes), and the staging laparotomy (a surgical biopsy ofmultiple organ sites).49 While we
44AsTubianaexplains, radiationtherapy "requires 46M Vera Peters, 'Prophylactic treatment of
great skill" and "remains technically difficult", thus adjacent areas in Hodgkin's disease', Cancer Res.,
the "unfavorable results ofradiation therapy and the 1966, 26: 1232-43, p. 1240.
hightoxicity initially associated withradiation therapy 47C Gordon Zubrod, 'Summary ofinformal
in some centers [in Europe, in the 1960s] were due in discussion on: Radiation therapy', CancerRes., 1966,
part to inadequate equipment but mainly to the 26: 1264-7, p. 1264.
insufficient experience ofthe team". Tubiana, op. cit., 48H S Kaplan and S A Rosenberg, 'Extended-field
note 20 above, p. 27. radical radiotherapy in advanced Hodgkin's disease:
45In a retrospective review of the treatment of short-term results of 2 randomized clinical trials',
Hodgkin's, Rosenberg claims that Peters adopted a CancerRes., 1966, 26: 1268-76.
"concept of unicentric origin and orderly 49On these techniques, see J B Kinmonth,
progression and treated patients with extended G W Taylor, and R K Harper, 'Lymphography:
fields ofradiation". Rosenberg, op. cit., note 23 a technique for its clinical use in the lower limbs',
above, p. 51. Br. med. J., 1955, i: 940-2; B J Lee, J H Nelson,
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cannot deal with these techniques here, it shouldbe noted thatthey considerably expanded
theclinical dataandthustheprognosticpossibilities inherentintheclinicaltrialsconducted
to date.50
Histories of Hodgkin's disease vary little in their evaluation of the contributions of
staging, in general, and Kaplan and Rosenberg's theory, inparticular. Here is arecapitula-
tion of what has so far been presented in a history of Hodgkin's therapy in Europe:
The irradiation ofthe neighbouring uninvolved lymphatic areas, as performed in Toronto by Peters
was controversial. Moreover, Kaplan in 1965 had developed an irradiation technique in which all
the lymphatic areas located on the same side ofthediaphragm were irradiated by single anteriorand
posterior fields. The rationale behind this technique was based on three assumptions: (a) the disease
spreads via lymphatic channels to contiguous lymph node chains and otherlymphatic structures; (b)
the diaphragm represents a boundary between the upper and lower torso; and (c) the progression
from stage II ... to stage HI ... corresponds to a marked increase in the seriousness ofthe disease.5'
Similarly, but considerably more briefly, the Italian Hodgkin's specialist, Gianni Bona-
donna,lists "1965RosenbergandKaplan: Evidenceforanorderlyprogressioninthespread"
as amajorturning pointinhis 'Chronological flowofmajorconcepts andeventsinfluencing
theevolutionofthetreatmentofHodgkin'sdisease'.52Likewise,inalistof"majoradvances
inHodgkin's disease", VincentDeVitaandGeorgeCanellossingleoutthediscoveryofthe
contiguous, orderly progression and the related staging system for special attention:
3. Description of the mode of spread of the disease, which was contiguous, unlike other
malignancies (Gilbert, Peters, and Kaplan)
4. Staging system, which was based on the data on the mode ofspread, andproved to be aprototype
of staging classifications for other malignancies (Kaplan and others).53
Finally, recent work continues to recognize the unequivocal importance of this break-
through. A 1998 radiotherapy study of Hodgkin's patients begins by stating: "Advance-
ments made intheradiotherapy ofHodgkin's disease may beattributed, by andlarge, to an
improved understanding of its mode ofprogression".54
So,whathavewelearned?First,thenotionofclinical stagesinHodgkin'sdiseaseclearly
emerged ahead of and outside biological and pathological theories of the spread of the
disease. Second,thestages weregroundedinclinicalobservationconcerningtherecurrence
ofthe disease following therapy. Third, using the stages, Lukes created ahistopathological
classification ofHodgkin's disease that generated further prognostic information. Fourth,
and G Schwarz, 'Evaluation oflymphangiography, in Hodgkin's patients whose immune system is
inferior venocavography and intervenous compromised and who are thus more likely to suffer
pyleography in the clinical staging and management infection. One co-operative study, for example,
of Hodgkin's disease and lymphosacoma', N. Engl. showed the procedure to have 6 per cent mortality.
J. Med., 1964, 271: 327-37; E Glatstein et al., S Hellman, 'Current studies in Hodgkin's disease:
'The value of laparotomy and splenectomy in the whatlaparotomy haswrought', N. Engl.J.Med., 1974,
staging ofHodgkin's disease', Cancer, 1969, 24: 290: 894-8.
709-18. 51Tubiana, op. cit., note 20 above, p. 27.
50Begun in the late 1960s, the staging laparotomy 52Bonadonna, op. cit., note 25 above.
allows for what is termed "pathological staging" as 53VincentTDeVitaJrandGeorgePCanellos, 'The
opposedto "clinicalstaging".Glatsteinetal.,ibid.Asa lymphomas', Semin. Hematol., 1999, 36: 84-94, p. 85.
major surgical procedure requiring complete 5 Stephen Ludwig Roth etal., 'Contiguous pattem
anaesthesia, the staging laparotomy bears the risks spreading in patients with Hodgkin's disease',
associated withall surgery. Thisisparticularlythecase Radiother. Oncol., 1998, 47: 7-16, p. 7.
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the appearance ofmultiple theories ofthe spread ofHodgkin's did nothing to diminish the
utilityofPeters' stages. Allclinical trialscontinuedtousethe stagesas astartingpoint. The
stages were, in other words, relatively invulnerable to changes in biology and pathology.
The theories ofthe spread ofHodgkin's were not, ofcourse, useless. As a recent editorial
concerning the spread ofHodgkin's recognized, regardless of the exact nature of a "cor-
rect" theory, KaplanandRosenberg's "hypothesis" "constitutedtherationale toundertake
large prophylactic irradiation" and continues to have relevance today.55 The relative
autonomy ofthe Hodgkin's staging system, first codifiedin Paris and Rye, was reaffirmed
in subsequent reforms known as the Ann Arbor (1971) and Cotswolds (1979) reforms.56
No such elucidation occurred with the non-Hodgkin's lymphomas. Briefly, the staging
systemthatworkedsowellinHodgkin'sprovidedrelativelylittleprognosticinformation in
the case of the lymphomas. Clinical researchers consequently turned to the histopatholo-
gicalclassificationforguidance. Here, however, theimmunological revolutionoftheearly
1970sunderminedthebiologicalbasis ofthehistologyleadingtoaseriesofreforms that, in
the end, forced clinicians to accept aclassification that made no pretence ofprognosis and
that was, in fact, openly hostile to such attempts.
Non-Hodgkin's Lymphomas and the Confrontation of Biology and Pathology
Until the advent ofcombination chemotherapy in the late 1960s, the treatment of non-
Hodgkin's lymphomas, like that of Hodgkin's, consisted mainly of radiation. As with
Hodgkin's disease, the tumour, node, metastasis staging (TNM) was not appropriate. In
the case ofthe lymphomas, this was inpartbecause there is no way to determine the site of
origin of the disease. Consequently, it is impossible to distinguish between the three
elements of the TNM system.57 Most radiotherapists had, by then, adopted Peters' and
laterthe Rye staging system fortheNHLs, inpartbecause they treatedboth Hodgkin's and
the NHLs. The National Cancer Institute Radiation Branch, for example, had adopted
Peters' classification in a pilot study of radiation therapy for stage three and four NHLs
initiated in 1964.58 Thus, following the acceptance of the Paris-Rye conventions for the
stagingofHodgkin'sdisease,clinicalresearchersinthefieldofchemotherapyproposedthe
adoption of a similar system for the NHLs.59
55Patrice Carde and Evert M Noordijk, 'Studying
spreadingpattern inHodgkin's disease: is itrelevant to
modern cancer treatment?', Radiother. Oncol., 1998,
47: 3-5, p. 3.
56On the Ann Arbor revisions, see for example,
Ultmann and Moran, op. cit., note 37 above. For the
report ofthe Cotswolds meeting, see A Lister et al.,
'Report of a committee convened to discuss the
evaluation and staging ofpatients with Hodgkin's
disease: Cotswolds meeting', J. Clin. Oncol., 1989,
7: 1630-6.
57For a recent overview of staging NHL, see
Lena Specht, 'Staging systems and staging
investigations', in Magrath (ed.), op. cit., note
10 above, pp. 533-53.
58See Ralph E Johnson, Gregory T
O'Connor, and David Levin, 'Primary
management of advanced lymphosarcoma with
radiotherapy', Cancer, 1970, 25: 787-91,
p. 787. Peters' classification applied to the NHLs
can be found in M V Peters, R Hasselback, and
T C Brown, 'The natural history of the
lymphomas related to the clinical classification',
in C Zarafonetis (ed.), Proceedings ofthe
international conference ofleukemia-
lymphoma, Philadelphia, Lea & Febiger, 1968,
pp. 357-71.
59The Committee for the Study of Malignant
Lymphomas ofthe National Cancer Institute of Milan
wasthefirsttomake suchaproposal. SeeAlbertoBanfi
et al., 'Proposta di classificazione et criteri terapeutici
del linfosarcoma edelreticulosarcoma', Tumori, 1965,
51: 153-78.
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Althoughradiotherapists notedthatsurvivalrateswereconsiderablysuperiorforpatients
with truly localized disease,60 unlike Hodgkin's the lymphomas rarely presented them-
selves as localized in the lymph nodes, and patients with stage two and beyond rarely
survived.61 Moreover, the spread ofdisease in the lymphomas did not follow the orderly
pattern observed in Hodgkin's, so rendering the prophylactic radiation strategy useless.62
These observations were subsequentlyrestatedbychemotherapists in a series ofstudies on
thepattern ofspreadandinvolvementdatingbacktothebeginningsofcombinationtherapy
in the early 1970s.63
None the less, throughout the 1970s and 1980s, co-operative group trials continued to
report their results in terms of stages, and investigators sought prognostic information
within the stages. For example, Bartolucci, Durant and Gams found that spread of the
disease beyond the lymph nodes was prognostically bad.64 Moreover, even though
Rosenberg had pronounced the staging system of limited value in 1977 and despite the
development of over twenty alternative systems in the 1980s,65 the Ann Arbor (1971)
modification of the Rye system remained the most commonly used.66 Even though it
provided little prognostic or therapeutic information, it did enable investigators to isolate
the few cases amenable to radiation therapy (stage one) andto use "a standardizedmethod
by which to classify patients for comparison of clinical trials".67
60ALipton and Burton J Lee, 'Prognosis ofstage I
lymphosarcoma and reticulum cell sarcoma', N. Engl.
J. Med., 1971, 284: 230-3.
61R E Johnson, G T O'Conor, and D Levine,
'Primary management ofadvanced lymphosarcoma
with radiotherapy', Cancer, 1970, 25: 787-91; R C
Young et al., 'Advanced lymphocytic lymphoma:
Randomized comparisons ofchemotherapy and
radiotherapy alone or in combination', Cancer Treat.
Rep., 1977,61: 1153-9; JTChaffey etal., 'Total-body
irradiationinthetreatmentoflymphocyticlymphoma',
Cancer Treat. Rep., 1977, 61: 1149-52; S C Carabell
etal., 'Results oftotalbody irradiation inthe treatment
of advanced non-Hodgkin's lymphomas', Cancer,
1979, 43: 994-1000; H C Boston et al., 'Malignant
lymphoma (so-calledreticulum cell sarcoma) ofbone',
Cancer, 1974,34: 1131-7;CCWangandDJFleischli,
'Primary reticulum cell sarcoma of bone. With
emphasis on radiation therapy', Cancer, 1968, 22:
994-8; J Newall and M Friedman, 'Reticulum-cell
sarcoma. Part III. Prognosis', Radiology, 1970, 97:
99-102; T R Miller and J T Nicholson, 'End results in
reticulum cell sarcoma ofbone treated by bacterial
toxin therapy alone or combined with surgery and/or
radiotherapy (47 cases) or with concurrent infection
(5 cases)', Cancer, 1971, 27: 524-48.
62See, for example, the cases collected and
reviewed in Hanne Sand Hansen, 'Reticulum cell
sarcoma treated by radiotherapy. Significance of
clinical features upon the prognosis', Acta Radiol.
Ther. Phys. Biol., 1969, 8: 439-58; Urpo Tikka and
Kai Malmio, 'Clinical and radiotherapeutic aspects of
reticulumcellsarcoma',ActaRadiol. Ther.Phys.Biol.,
1969, 8: 459-70; Leonard R Prosnitz et al., 'The
clinical course of Hodgkin's disease and other
malignant lymphomas treated with radical
radiation therapy', Am. J. Roentgenol., 1969, 105:
618-28.
63D R Goffinet et al., 'Clinical and surgical
(laparotomy) evaluation ofpatients with non-
Hodgkin's lymphomas', CancerTreat.Rep., 1977, 61:
981-92; B A Chabner et al., 'Sequential nonsurgical
and surgical staging ofnon-Hodgkin's lymphoma',
Cancer, 1978, 42: 922-5; J D Bitran et al.,
'Non-Hodgkin's lymphoma, poorly differentiated
lymphocyticandmixedcelltypes.Resultsofsequential
stagingprocedures,responsetotherapy,andsurvivalof
100 patients', Cancer, 1978, 42: 88-95; T Anderson
et al., 'Malignant lymphoma: I. The histology and
stagingof473patientsattheNationalCancerInstitute',
Cancer, 1982, 50: 2699-707; The Non-Hodgkin's
Lymphoma Pathologic Classification Project,
'National Cancer Institute sponsored study of
classifications ofnon-Hodgkin's lymphomas:
summary and description of a working formulation
for clinical usage', Cancer, 1982, 49: 2112-35.
64A Bartolucci, J R Durant, and R A Gams,
'Prognostic factors in non-Hodgkin's lymphomas: a
multivariate analysis ofover 300 cases', ASCO, 1977,
18, p. 304; and N I Nissen et al., 'Overview of four
clinical studies ofchemotherapy forstageHII andstage
IV non-Hodgkin's lymphomas by the Cancer and
Leukemia Group B', Cancer Treat. Rep., 1977, 61:
1097-107.
65The various systems are described in Specht,
op. cit., note 57 above.
66JAMoormeier, SFWilliams, andHMGolomb,
'The staging ofnon-Hodgkin's lymphomas', Semin.
Oncol., 1990, 17: 43-50, p. 43. 67Ibid.
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Giventhedrawbacks, anddespitethecontinueduseofclinical staging,clinicianresearch-
ers came to see the management of the NHLs according to histology as far more satis-
factory from the point ofview ofprognosis. So, when the NCI co-operative clinical trials
groups began chemotherapy trials with the NHLs at the end of the 1950s, they recruited
RobertLukes to develop apathological classification ofthe non-Hodgkin's lymphomas.68
To do so, Lukes drew on the work of a former colleague at the US Army Institute of
Pathology, Henry Rappaport. A well-known Chicago pathologist, Rappaport had been
contracted by the Army Institute in the mid-1950s to produce a tumour atlas covering
tumours of the lymphatic system, including Hodgkin's disease. The Army Institute had
commissioned Rappaport after rejecting as somewhat "self-righteous" a manuscript sub-
mittedonthesametopicbyRPhilipCuster.69Basinghisclassificationonthevastcollection
maintained by the Army Institute ofPathology, Rappaport proposed a fundamental reor-
dering ofthe lymphomas that added an explicit prognostic/clinical dimension to what had
been mainly a diagnostic/histopathological classification.70
Rappaport's prognosis wasembeddedinpartin a new architectural analysis ofthe lymph
node biopsy specimens. This distinguished between lymph nodes that appeared to have
enlarged follicules or nodes, and those-termed diffuse-that did not. First published in
schematic form in the mid-1950s, Rappaport's classification divided the former into five
cytological types, the last being Hodgkin's which, given the singularity represented by the
Reed-Stemnberg cells, he and his colleagues admitted did not seem to have much business
being there. Based mainly on size, the designations were not simply visual. In so far as size
indicated a stage oflymphocyte development, large cells represented those inthe process of
proliferation.Cliniciansandpathologistscouldthusattributetolymphomascomposedmainly
oflarge cells the properties associated withrapid growth, namely a more aggressive clinical
evolution. When the system appeared ten years later in 1966 as part ofthe Atlas ofTumor
Pathology-"one ofthe most influential publications in American pathology"71-it sold
morethananyotherfascicleofthatcollectionwithtotal salesworldwide at 15,300copies.72
68See Peter Keating and Alberto Cambrosio,
'From screening to clinical research: the cure of
leukemia andtheearlydevelopmentofthecooperative
oncology groups: 1955-1966', Bull. Hist. Med., 2002,
76: 299-334.
69SeeArthurPurdySout,Chairman, Subcommittee
on Oncology to Henry Rappaport, Mt Sinai Hospital,
Chicago, Ill., 14April 1956, ArmedForces Institute of
Pathology Archives, Correspondence, 1956-1961. As
F W Stewart ofthe publication committee had
remarked when Rappaport finally submitted his
monograph, "It [Rappaport's manuscript] lacks the
self-assured righteousness ofthe Custer monograph
that we had to reject". F W Stewart to Catherine
Blumberg, 30 Dec. 1959, Atlas ofTumor Pathology,
'Criticism and Critical Reviews', Box 31, Armed
Forces Institute of Pathology Archives.
70See H Rappaport, W J Winter, and E B Hicks,
'Follicularlymphoma. Are-evaluation ofitspositionin
the scheme ofmalignant lymphoma based on a survey
of 253 cases', Cancer, 1956, 9: 792-821. This paper
became the basis of the 1966 classification published
as H Rappaport, Tumors ofthe hematopoietic system.
Atlas oftumorpathology, Section 3, Fascicle 8,
Washington, DC, US Armed Forces Institute of
Pathology, 1966. The ten-year delay can be largely
explainedby administrative problems within the Army
Institute of Pathology.
71Juan Rosai to William Hartmann, 31 May 1977,
'Fascicles Editorial Advisory Committee',
Correspondence, Army Institute of Pathology
Archives, 1977.
72Army Institute of Pathology, Annual Report,
1972, p. 116. As the director of the Atlas ofTumor
Pathology noted at the time: "As I understand it, ithas
always been customary to print about 5,000 to 6,000
copies ofeach fascicle and then when the supply runs
low toreprint until 15,000 copies have been printed. In
the case of Tumors ofthe Hematopoietic System, the
marketwas sothirsty andthe Fascicle so superbthatall
the copies were gone in about five months". Harlan I
Firminger to Henry Rappaport, 23 May 1967, Box 31,
Correspondence, Army Institute of Pathology
Archives, 1961-1967.
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As head of the Pathology Advisory Committee of the NCI clinical cancer trial groups
programme, and in the absence of a staging system for the non-Hodgkin's lymphomas,
Lukes needed a "provisional classification and grouping" ofthe latter in order to organize
patients into histopathological diagnostic groups. The 1956 version ofRappaport's system
providedjustsuchcriteriawiththeaddedprognosticbonus.Notingthatthesystemwouldbe
"subject to verification on the basis of future experience", Lukes outlined the possible
pitfalls ofsuch abootstrapping operation. The serial correctionproposed by the Pathology
Advisory Committee-start with simple categories and see what turns up-presupposed
thatthelargecategoriesthemselvescouldbeeasilyfilled.AsLukesdemonstrated,however,
pathologists could be consistently confounded in the diagnosis of lymphomas, notably in
confusing the benign with the malignant, the most important prognostic categories ofall.
Partly because ofconsiderable visual overlap between entities, histopathologic diagnosis
was further complicated by the fact that many ofthe preparations involved manual tech-
niques. In some instances, the only way to ensure consistency of preparation was to
institutionalize bias: Lukes' group, for example, employed "one specially trained techni-
ciantoprepare allthehistologic sections".73Moreover, ateamofthreepathologists headed
by Lukes studied all histology sections prepared for the Southeastern group at the Army
Institute ofPathology, reaching diagnosis by consensus. This careful pathology was only a
beginning. Thus, Lukesbelievedthat, ultimately, itwouldbe "essential forthepathologists
ofeach study group to collaborate in a comparative study ofhistologic case material in an
attempt to achieve uniform criteria for diagnosis and classification ofthe lymphomas".74
The large-scale clinical trials for non-Hodgkin's lymphomas that emerged at about the
time of the Rye conference further bolstered the value of histologic management and
Rappaport's classification. Following the formation of the task forces by the NCI, and
in order to ensure uniformity of diagnosis in the lymphomas and thus to ensure compar-
abilityoftreatmentresults,theLymphomaTaskForce setupapathologypanelrunthistime
by Rappaport himself. Reporting to the Lymphoma Task Force in 1967, Rappaport noted
thatthepathologypanelserved "asacriticalreferenceforthediagnosisandclassificationof
pathologic specimens from patients with lymphomas entered in co-operative group
chemotherapy protocols".75 As head ofthe panel, Rappaport was in aposition to mandate
his prognostic-histopathologic system for the lymphomas as a progressively widening
standard. The fact that the late 1960s had also seen the introduction of a "standard"
chemotherapy treatment (CHOP) meant that a growing number of phase two and phase
three protocols were needed to extend the original findings (phase one) and compare
alternatives to the standard (phase three). From 1970 to 1977, the total number of lym-
phomachemotherapyprotocols (includingbothHodgkin'sdiseaseandNHL)doubledfrom
fifteen to thirty. Between 1967 and 1976, the panel reviewed 5,375 cases, and so collected
almost as many cases in nine years as the US Army Institute of Pathology had in thirty
73Robert J Lukes, 'Investigations in malignant 75Minutes of the Lymphoma Task Force, 16 June
lymphomas', in Conference on experimental clinical 1967,p. 1. NCIArchives. AR-6802-001829. ThePanel
cancer chemotherapy, National Cancer Institute hadheld its first organizational meeting in March. The
Monograph No. 3, Washington, U.S. Government minutesofthatmeeting are includedin the appendix to
Printing Office, 1960, pp. 193-312, on p. 199. the present document. See National Cancer Institute,
74Ibid., p. 200. Lymphoma Task Force, Pathology Panel, Bethesda,
Maryland, 9-10 March 1967.
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years.76 The fact that by the mid-1970s the panel reviewed and classified around 1,000
slides a year according to the Rappaport system, gave them unparalleled expertise and
Rappaport's systemunparalleled authority inthefieldofthenon-Hodgkin's lymphomas.
Buoyedbyitsrecognizedprognostic significance andstatuswithintheAmericanclinical
trial system, Rappaport's system thusbecame the classification for "pathological staging"
forclinical trialsintheUnited States.78 Astestimony toitswidespreaduse, whenreviewing
the methods and strategies ofco-operative clinical trials in the late 1970s, Franco Muggia
and his colleagues at the Southwest Oncology Group79 concluded that one of the char-
acteristics of the 1970s had been the "individualization of protocols for favourable and
unfavourable histologies according to the Rappaport classification".80 Yet, despite its
acceptance,problemsplaguedtheRappaportsystemthroughoutthe 1970s.Theuseofhistology
ratherthanstagingtomanagepatientsbroughtclinicianstreatingNHLsintoclosercontactwith
"biological" reality than clinicians who treated Hodgkin's. Prognostic stages could be used
within atherapeutic strategy regardless ofthe underlying biology ofthe spreadofHodgkin's;
with NHLs, however, each histologic entity referred, in principle, to a different underlying
biological entity: the cell oforigin. Ifthe biology changed, so did the pathology. Thus, when
the biology ofthe immune system changed during the 1970s with the rise ofcellular immu-
nologyandtheconstitutionofnewentitiesknownasTandBcells,ithadamoreimmediateand
direct impact on the management ofNHLs than on the management of Hodgkin's.
In the early 1970s, a series of alternative classifications emerged that claimed to make
better sense biologically of the different forms of lymphoma even though they did not
necessarily improve management. Underpressure from these "immunological" analyses,
the cells known to pathologists as histiocytes, for example, began to appear in quotation
marks signifying their uncertain status. The most damaging work appeared in the early
1980s when large-scale studies showed that the histiocytes were, in fact, what immunol-
ogists had been calling B-cells for some ten years.8' Some users ofthe Rappaport system
76Between 1925 and 1954, the American Lymph
Node Registry, transferred to the Army Museum (later
Institute) ofPathology during the 1930s, collected
5,500 cases. AnnualReport, Armed Forces Institute of
Pathology, 1954, p. 19.
77The Center also received specimens from the
Hodgkin's disease radiotherapy group and "Personal
referrals from many sources". See 'Clinical
cooperative group program: Clinical trials review',
Memorandum from the Associate Branch Chief,
Clinical Investigations Branch (Edwin Jacobs) to Dr
John Macdonald, Associate Director, Cancer Therapy
Evaluation Program, 28 Nov. 1978, p. 48, NCI
Archives.
78See for example, M J Lotz et al., 'Pathological
stagingof 100consecutive untreatedpatients withnon-
Hodgkin's lymphomas: extramedullary sites of
disease', Cancer, 1976, 37: 266-70.
79A history of the group entitled 'The history and
evolution of the Southwest Oncology Group' can be
found at their website at www.swog.org.
80F M Muggia, H L Davis, and M Rozencweig,
'Current cooperative clinical trials in the non-
Hodgkin's lymphomas', Cancer Treat. Rep., 1977, 61:
1191-7.
81 See forexample, RJ Lukes etal., 'Immunologic
approach to non-Hodgkin lymphomas and related
leukemias. Analysis of the results of multiparameter
studies of425 cases', Semin. Hematol., 1978, 15:
322-51, and R J Lukes et al., 'A morphologic and
immunologic surface marker study of 299 cases of
non-Hodgkin lymphomas and related leukemias', Am.
J. Pathol., 1978, 90: 461-85. Ironically, Rappaport's
classification had originally been resisted on similar
grounds of mis-identification ofcells. Some
pathologistsfelt,forexample,thatRappaporthadfailed
to show, on morphological grounds, that the histiocyte
existed where indicated on the slides. As one reviewer
of Rappaport's contribution to the Atlas ofTumor
Pathologyputit, "OneofthefeaturesofDrRappaport's
classifications and nomenclature is that, by and large,
he has substituted the word 'histiocyte' for 'reticulum
cell'. He does this on the ground that the histiocyte is a
differentiated cell distinguishable from
undifferentiated reticulum cells by the metalophil
properties [silver-staining] as indicated by Marshall.
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saw no reason to abandon this clinically useful framework. Leadresearchers in lymphoma
chemotherapy at the NCI, for example, cheerfully admitted that though the category was
"scientifically incorrect", it was still "clinically relevant".82 Fortheirpart, Rappaport and
his colleagues claimed in a subsequent study comparing the immunological and histolo-
gical systems that "diffuse histiocytic lymphomas" were better prognosticators than the
83 Hri a corresponding immunological categories. Herein lay the dilemma. In the lymphomas,
prognosis depended less on disease extent (clinical staging) than histopathologic subtype
(pathologic staging). Indeed, investigators typically staged according to histology and
distinguished between "good" histologies (nodular) and "bad" histologies (diffuse).84
The problem with this prognosis was the status ofthe entities whose future the Rappaport
system purported to describe: from a biological perspective, as we havejust seen, they no
longer existed.
Rappaport's system was further compromised in the late 1970s by user complaints
suggesting that without the centralized review offered by the expert pathologists serving
on Rappaport's panel, use of Rappaport's system in the co-operative groups gave mixed
results. AstudybytheSouthwestOncology Groupshowedthatthedegreeofagreement(on
both type and subtype) between the members ofthe Lymphoma Pathology Review Panel
and hospital pathologists was a mere 58 per cent.85 A study conducted by the Eastern
Cooperative Oncology Group gave similar results: in a series of535 cases, despite 96 per
centagreementonthediagnosis ofNHL, whenitcametothecruxofRappaport's system-
cell type and pattern-agreement fell to 79 per cent.86 The Southeastern Cancer Study
Group found even less accord.87
Yet nowhere in the fascicle do we find descriptions or
illustrations ofapplicationsofthemetalophil methodto
supportthe designationofcertaincells ashistiocytes or
ofhistiocyticderivation".ClydeJDaweto 'Review' 22
Jan. 1960, Atlas ofTumor Pathology, 'Criticism and
Critical Reviews', Box 31, Armed Forces Institute of
Pathology Archives.
82They proposed, in particular, that further
morphological analysis would allow clinicians to
subdivide the category into two different groups with
differingprognosesandthathavingreworkedtheirown
data, proposed to others that "Morphologic
subclassification ofdiffuse 'histiocytic' lymphoma
may be useful in predicting response to chemotherapy
and survival". J A Strauchen etal., 'Clinical relevance
of the histopathological subclassification ofdiffuse
"histiocytic" lymphoma', N. Engl. J. Med., 1978, 299:
1382-7, p. 1382. Indeed, as explicitly stated by an
international panel ofexperts set up in the early 1980s
by the NCI to study the problem, The Non-Hodgkin's
Lymphoma Classification project: "One of the most
controversial aspects of the Rappaport classification
concerns the group oftumors included within 'diffuse
histiocytic lymphoma'. The term 'histiocytic' is now
knowntobe, insomeinstances, scientificallyincorrect.
The large cells found in these neoplasms are in most
cases derived from lymphocytes, while lymphomas of
true histiocytic nature are rare." The Non-Hodgkin's
Lymphoma Pathologic Classification Project, op. cit.,
note 63 above, p. 2120.
83B NNathwani etal., 'Theclinical significance of
the morphological subdivision ofdiffuse "histiocytic"
lymphoma: a study of 162 patients treated by the
Southwest Oncology Group', Blood, 1982, 60: 1068-
74, p. 1068.
84As summarized in a review ofco-operative
group trials prepared for the Division of Cancer
Treatment: "Prospective trials from all cooperative
groups have confirmed the better responsiveness and
superior survival of the lymphomas with a nodular
pattern (good risk or favourable histologies) versus
those of the diffuse type (poor risk or unfavorable)."
Charles A Coltman et al., 'Lymphoma', in Barth
Hoogstraten (ed.), Cancer research: impact of
the cooperative groups, New York, Masson,
1980, pp. 39-84, on p. 68.
85S E Jones et al., 'Histopathologic review of
lymphomacasesfromtheSouthwestOncologyGroup',
Cancer, 1977, 39: 1071-6.
86E Ezdinli et al., 'Eastern Cooperative Group
experience with the Rappaport classification of non-
Hodgkin's lymphoma', Cancer, 1979, 43: 544-50.
87Using an outside referee to review 406 cases
diagnosedbylocalpathologists,theyfoundonly48 per
cent agreement. These unpublished findings were
reported in Coltman, op. cit., note 84 above, p. 61.
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The development ofimmunology-based classifications engendered yet anotherproblem
thatwentbeyondtheirapparentlackofprognosticcontent: weretheclassificationsmutually
compatible? Anearly studycarried outbytheEuropeanLymphoma Club inthe mid-1970s
showed, paradoxically, that although the classifications were comparable, it was mainly
because pathologists had equal difficulty in reproducing them.88 According to the study
protocol, Club members classified fifty cases oflymphoma according to each ofthe three
major classification schemes then available (Rappaport, Lukes-Collins and Kiel). Three
independent observers then reclassified the same cases. The degree ofagreement between
the two groups of classifiers barely went beyond random (50 per cent) in the case of the
Rappaport classification and reached an unimpressive 60 per cent in the case of the Kiel
classification.89
Following a series ofconferences organized to iron out the differences between classi-
fications, the WHO attempted to translate between systems. Rappaport had organized the
first meeting entitled 'Workshop on Classification of Non-Hodgkin's Lymphomas' in
Chicago in June 1973. The major protagonists came together the next year at the first
international conference onlymphomaclassificationheldinLondon. Optimismranhighas
Henry Kaplan wrote in the introduction to the published proceedings:
It may confidently be predicted that pathologists will soon acquire an exciting new armamentarium
of differential tests based on surface membrane receptors and other distinctive cytochemical and
immunological properties of these cells and that histopathological classifications firmly rooted in
these fundamental biological attributes will emerge.90
In the meantime, however, what did happen was the generally considered "Florence
fiasco": the International Cancer Conference held in Tuscany in 1974, in the course of
which irreconcilable differences became evident. Lack ofconsistent clinical data and treat-
mentprogrammesrenderedthebasisforcomparisonsubjecttofurthercontroversy. SoKaplan
convened yet another conference (Virginia, 1975) fundedby the American National Cancer
Institute.91 By invitation only, the conference was closed tooutsiders in an attempt tokeep
the heat down. The meeting achieved no consensus.92 In order to overcome the clinical
inconsistencies, therefore, the NCI had first to generate common clinical data using pre-
viously untreated patients. The NCI thus decided to organize its own series of cases
especially for the purpose of comparing the classification systems. Four institutions-
three American and one European-were chosen to provide the cases for review.93
Theresults ofthe showdown were discussed atconferences held atStanfordin 1979-80,
and the participants agreed that no fundamental differences had surfaced with regards to
88The Club was createdby Karl Lennert in 1973 as 91Entitled the 'Invitational Workshop for the
a vehicle for the Kiel classification. Planning ofRetrospective and Prospective Studies to
89KLennert and H Stein, 'Personal points ofview DelineateOptimalClassificationoftheNon-Hodgkin's
on the Kiel classification', in GMath6 and M Tubiana Lymphomas', the meeting was held in Warrenton,
(eds), Lymphoid neoplasms I: classification, Virginia, 4-5 Sept. 1975. See GMathe, 'Workshop for
categorization and natural history, Berlin, Springer, the classification ofnon-Hodgkin's lymphoma',
1978, pp. 31-7, on pp. 35-6. Biomedicine, 1975, 22: 466-7.
90H S Kaplan, 'Introduction', Br. J. Cancer, 92Ibid.
Supplement2, 1975,31: vii-viii.QuotedinCWBerard 93The institutions were: Istituto Nazionali Tumori,
and R E Hutchison, 'The problem ofclassifying Milan, Italy; University of Minnesota Hospitals,
lymphomas: anorderlyprescription forprogress',Ann. Minneapolis, Minnesota; Tufts-New England Medical
Oncol., Supplement 2, 1997, 8: S3-S9, p. S4. Center, Boston, Massachussetts; Stanford University
Medical Center, Stanford, California.
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reproducibility. As to the prognostic value of the systems, investigators found that while
none stood out as particularly good, none stoodout asparticularly poor.94Inthe absence of
clinical features distinguishing the systems, then, the investigators developed a "Working
Formulation" (WF). Drawing histologic terminology from the Rappaport and Lukes-
Collins classifications, the group offered the formulation not as a new classification,
"but as a means of translation among all systems".95 Published in 1982, the WF went
on to become the classification ofchoice in North America. A 1988 study ofpathologists
showed thatover97percentusedtheWFwhereasonly 5 percentwere "familiar" withthe
competing ("European") Kiel system. Intended primarily for clinical use, the WF had a
morphologicbase(topleasethepathologists) withaprognostic superstructure(topleasethe
clinicians). Borrowed from the Kiel system and based "primarily upon differences in
survival",96 the latter included three categories: high grade, intermediate grade and low
grade.97 The grading system and the Working Formulation henceforth replaced the patho-
logical staging adopted atAnnArborin 1971, althoughthe termAnnArborcontinuedtobe
used to signify both the clinical staging and the new WF pathological staging.98
Notalltheexperts werepleasedwiththeWF. UnliketheHodgkin'spathological staging,
the different histological categories in NHLs referred to different entities, and not to
different stages in the development of a single entity. By combining entities within a
prognostic-graded-superstructure, theWFcreated atensionbetweenclinical considera-
tions and biology that had been absent in the case of Hodgkin's disease. The German
pathologist (and champion of the Kiel classification) Karl Lennert, for example, offered
two reservations that were ultimately to lead to the abandonment of the Formulation:
"Firstly, within this Formulation lymphomaentities which are biologically closely related
are separated and entities biologically unrelated are grouped together. Secondly, all con-
siderationsregarding immunologic identitiesoflymphomashavebeenexcluded".99Lukes
concurred.'°° None the less, even though biology and immunology had notbeen included,
Rappaport noted that they had not been precluded, adding, somewhat demurely, that they
could be "readily added when future research establishes their clinical value above and
beyond that of the histologic classification". Rappaport, moreover, pointed out with a
certain sense of vindication that "the clinical relevance of pattern was recognized and
the terms 'follicular' and 'diffuse' were made part of the new formulation".'01
However,theWFultimately satisfiedneitherthepathologists northeclinicians. Fromthe
clinical point ofview, the grading system was only partly successful. By the early 1990s,
clinicians classified the intermediate and high-grade lymphomas together under the rubric
of"aggressivelymphomas", asthedistinctionbetweenintermediateandhighmeltedaway.
94The Non-Hodgkin's Lymphoma Pathologic 'Pathology of malignant lymphomas', in Peter H
Classification Project, op. cit., note 63 above, Wiemik, George P Canellos, Robert A Kyle,
p. 2119. and Charles A Schiffer (eds), Neoplastic diseases of
95Ibid., p. 2121. the blood, New York, Churchill Livingstone, 1985,
96The Kiel "grades" can be found in K Lennert vol. 2, pp.707-36, on p. 712.
et al., 'The histopathology of malignant lymphoma', 98See for example, Moormeier, Williams, and
Br. J. Haematol., supplement, 1975, 31: 193-203. Golomb, op. cit., note 66 above, p. 44.
97The Non-Hodgkin's Lymphoma Pathologic 99Karl Lennert, 'Commentary on working
Classification Project, op. cit., note 63 above, p. 2122. formulation of non-Hodgkin's lymphomas', Cancer,
According toNCIresearchers, inclinicalprotocolsonly 1982, 49, p. 2133.
the categories "high grade" and "low grade" were l'°Ibid., p. 2134.
used. See Albert J Fomace Jr and Elaine S Jaffe, '01 Ibid.
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In fact, the two categories offered such a variety ofoutcomes that clinicians soon began to
look for other means ofpredicting results. Since a return to the Ann Arbor staging system
alonehadlittletoofferinthewayofprognosis, andsincetheWFgradeswerecompromised
bythefactthattherewerenowaplethoraofnationalhistopathological systemsthatallowed
one to grade a NHL, an international consortium of clinical trial groups set out at the
beginningofthe 1990stoproducewhatbecameknownastheInternationalPrognosticIndex
(IPI). Involving more than sixteen institutions worldwide, including eleven American and
European co-operative oncology groups, theconsortium assembled andexaminedanenor-
mous sample of over 3,000 intermediate and high-grade lymphoma patients treated with
chemotherapy between 1982 and 1987. Assessing the patients according to a variety of
factors such as age, Ann Arbor stage and such biological markers as blood enzymes, they
created an Index that when correlated with five-year survival rates divided the patient
population intofourdistinct groups with different survival rates.'02 Inotherwords, regard-
less ofthe different histopathological designations offered by the competing classification
systems,theIPIpredictedoutcomebasedon "clinical" asopposedto "pathological" status.
Subsequently validatedinanumberofforaandextendedtoadvancedHodgkin'sdisease,103
the IPI separated theproblems attendant upon identifying different species ofdisease from
the clinical demands ofpatient management and prognosis.104
Equally asdissatisfied with theWF, anumberofpathologists known astheInternational
LymphomaStudyGroupalsocametogetherintheearly 1990stocreate anewclassification
ofthe NHLs, the REALclassification.'05 The REALresponded to the criticisms ofpathol-
ogists like Lennert and Lukes in that it eschewed prognostic indications in favour of the
simple description of the entities involved and incorporated the newer cytogenetic and
immunological descriptions ofthe immune cells. Whenpresented to agroup oflymphoma
specialists notinvolvedintheREALinitiative atameetingheld attheNCI, however, some
participants-Rosenberg, forexample-feltthatthe new system sufferedsignificant short-
comings from a patient-management point of view.'06These objections were overcome
102The International Non-Hodgkin's Lymphoma
Prognostic Factors Project, 'A predictive model for
aggressive non-Hodgkin's lymphoma', N. EngI. J.
Med., 1993, 329: 987-94. The search continues for
improved biological markers. See U Axdorph et al.,
'Biological markers may add to prediction ofoutcome
achieved by the International Prognostic Score in
Hodgkin's disease', Ann. Oncol., 2000, 11: 1405-11.
103See C Gisselbrecht and C Ferme, 'Prognostic
factors in advanced Hodgkin's disease: problems and
pitfalls. Towards an international prognostic index',
Leukemia Lymphoma, supplement 1, 1995, 15: 23-4;
and Dirk Hasenclever and Volker Diehl, and the
International Prognostic Factors Project on Advanced
Hodgkin's Disease, 'A prognostic score for advanced
Hodgkin's disease', N. Engl. J. Med., 1998, 339:
1506-14.
104M A Shipp, 'Can we improve upon the
InternationalIndex?',Ann.Oncol.,supplement 1, 1997,
8: 43-7. C Stelitano et al., 'Validation of the
International Prognostic Index in working formulation
group A low-grade non-Hodgkin's lymphoma:
retrospective analysis of 137 patients from the Gruppo
Italiano per lo Studio dei Linfomi registry',
Haematologica, 2000, 85: 154-9; G Rossi etal., 'The
international prognostic index can be used as a guide
to treatment decisions regarding patients with human
immunodeficiency virus-related systemic non-
Hodgkin lymphoma', Cancer, 1999, 86: 2391-7, and
C S Chim et al., 'CEOP treatment results and validity
of the International Prognostic Index in Chinese
patients with aggressive non-Hodgkin's lymphoma',
Hematol. Oncol., 1998, 16: 117-23.
105Peter Keating and Alberto Cambrosio, '"Real
compared to what?" Diagnosing leukemias and
lymphomas', in Margaret Lock, Allan Young, and
Alberto Cambrosio (eds), Living and working
with the new medical technologies: intersections of
inquiry, Cambridge University Press, 2000,
pp. 103-34.
'06ProfessorTALister(Personalcommunication).
For Rosenberg's criticisms, see Saul A Rosenberg,
'Classification of the lymphoid neoplasms', Blood,
1994, 84: 1359-60.
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when clinicians and pathologists embarked upon the International Non-Hodgkin's Classi-
fication project setup to articulate the classification scheme withclinicalconcerns.107 The
REALhadfirstbeenpublishedin 1994. In 1997 amarginallymodifiedversionwasadopted
bytheWorldHealthOrganization asitsofficialclassification. TheWHOClinicalAdvisory
Committee noted in its report that the key issue was "to discriminate between disease
entities andprognosticfactors" (emphasis added).'08 The alliance between prognosis and
diagnosis created by Rappaport had come tobe viewed more as aproblem than a solution.
Conclusion
We have seen that with the rise of clinical research and clinical cancer trials, and the
subsequenttransformation ofnatural histories intotreatedhistories,prognosis hasemerged
asagoingconcernforclinicalresearchersconductingclinicaltrials. Here,theemphasiswas
not on prognosis as advice one would give to a patient as was the case prior to the Second
World War, but as a measure oftherapeutic efficacy and as an indicator ofthe biological
reactivity of the different species and subspecies of a particular class of entities to a
therapeutic regime. By focusing on populations rather than on individuals, prognosis
and prognostic information acquired as much a research value as a clinical value and,
in consequence, created a class of consumer that was not restricted to the ill: the clinical
researcher. In otherwords, as suggested at thebeginning ofthis paper, the post-warrise of
biomedicine resulted in a new configuration of medical practices. Formerly tied to the
doctor-patient relationship, prognosis, now the object of widespread clinical trials and
clinical research, has acquired a new epistemic and institutional meaning as a research
device. At the same time, in the field ofthe lymphomas, in keeping with the tendency to
analyse morbid entities and processes in biological terms, pathologists have sought to
extract "natural history" from "treatedhistory" bydisentangling diagnosis andprognosis.
This process was contingent in nature. Whereas radiotherapists transformed the natural
historyofHodgkin'sdiseaseandledinvestigations inthebiologyofitsspread,chemothera-
pists had relatively less impact on the understanding of the lymphomas. Change here
originated at the biological pole of the biomedical spectrum, when understanding of the
immune system was profoundly changed in the late 1960s and early 1970s. As we have
shown elsewhere, however, these changes in themselves were partly prompted by inves-
tigations inpathology.109Clinicalpathologists andchemotherapists subsequentlyfollowed
suitinthe 1980s,devisingclinicaltrialsaroundthenewbiomedicalentitiesknownasTcells
andBcells. TheadvantageofthecomparisonbetweenHodgkin's andtheNHLshereisthus
clear. The relative success ofthe Rye-Ann Arbor staging system in the case ofHodgkin's
7See The Non-Hodgkin's Lymphoma classification-from controversy to consensus:
Classification Project, 'A clinical evaluation of the The R.E.A.L. and WHO classification of
International Lymphoma StudyGroupclassification of lymphoid neoplasms', Ann. Oncol., supplement 1,
non-Hodgkin's lymphoma',Blood, 1997,89: 3909-18. 2000, 11: 3-10.
'08N L Harris et al., 'The World Health 09See Peter Keating and Alberto Cambrosio,
Organizationclassification ofneoplasticdiseasesofthe 'Transplantation, tumor or differentiation antigens?
hematopoietic and lymphoid tissues. Report of the The view from biology and the view from pathology',
Clinical Advisory Committee, Airlie House, Virginia, American Association for the History of Medicine,
November, 1997', Ann. Oncol., 1999, 10: 1419-32, 73rd Annual Meeting, Bethesda, Maryland, 18-21
p. 1421. N L Harris et al., 'Lymphoma May 2000.
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disease can be misleading for an understanding of the role of prognosis in modem bio-
medicine. Morethan aclinicalmethodforpredictingtherapeuticoutcomes, prognosis now
deals withuncertain outcomes inthe largerfieldofclinical research. As wehave seenwith
the NHLs, when prognostic information is drawn from natural history, the exploration of
prognosis simultaneously raises twoquestions: whatwillhappen to the patient and what is
the specific disease entity that we are treating? Changes inbiology necessarily change the
description ofdisease entities andthus impact much more directly uponpatientprognosis.
In this sense, biomedicine is a two-way street.
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